Evidence map›Paper›PMID 41159750›Full record

ArticleJournal of virology2025

Perturbed pediatric circulating metabolome in mild and severe dengue disease.

Paul S Soma, Rebekah C Gullberg, Barbara Graham, M Nurul Islam, Guillermina Kuan, Angel Balmaseda, Carol D Blair, Barry J Beaty, John T Belisle, Eva Harris and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paul S SomaDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-8544-4078
Rebekah C GullbergDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Barbara GrahamDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
M Nurul IslamDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Guillermina KuanSustainable Sciences Institute, Managua, Nicaragua.
Angel BalmasedaSustainable Sciences Institute, Managua, Nicaragua.
Carol D BlairDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-2803-0354
Barry J BeatyDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
John T BelisleDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, California, USA.ORCID 0000-0002-7238-4037
Rushika PereraDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-6798-2537

Funding

Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
Dengue Reporter Virus Neutralization Assay for Clinical StudiesR42AI062100 · NIAID · INTEGRAL MOLECULAR · PI HARRIS, EVA · 2007 to 2009
$2.7M
Metabolomics-based discovery of small molecule biomarkers for noninvasive dengueR33AI100186 · NIAID · COLORADO STATE UNIVERSITY · PI PERERA, RUSHIKA · 2014 to 2016
$1.3M
Dengue Reporter Virus Particle Neutralization AssayR41AI062100 · NIAID · INTEGRAL MOLECULAR · PI HARRIS, EVA · 2004 to 2005
$996k
Metabolomics-based discovery of small molecule biomarkers for noninvasive dengueR21AI100186 · NIAID · COLORADO STATE UNIVERSITY · PI BEATY, BARRY J · 2012 to 2013
$393k
NIAID NIH HHS R21 AI100186NIAID NIH HHS R33 AI100186NIAID NIH HHS R41 AI062100NIAID NIH HHS R42 AI062100NIAID NIH HHS U54 AI065359NIH HHS AI062100NIH HHS BAA-NIAID-DAIT-NIHAI2009061NIH HHS HHSN26620040001CNIH HHS R21NIH HHS R33NIH HHS U54
6 · The paper itself

Abstract

Four billion people are at risk of infection with dengue viruses (DENV), and this burden is rapidly increasing due to geographic expansion of the mosquito vector. Infection with any of the four serotypes of DENV can result in a self-limiting but debilitating febrile illness (DF), and some infections progress to severe disease with hemorrhagic manifestations and shock (dengue hemorrhagic fever/dengue shock syndrome [DHF/DSS]). DENV infection drives the metabolic state of host cells for viral benefit and induces a host-immune response with metabolic implications that link to disease. Here, a dynamic metabolic response to DENV infection and disease was measured in 535 pediatric patients from Nicaragua using liquid chromatography-tandem mass spectrometry. Metabolomic analyses revealed profound disruptions of critical biochemical pathways and metabolites within the circulating metabolome, especially in those with more severe manifestations of dengue disease. A biomarker panel of 28 metabolites was utilized to classify DF versus DHF/DSS with high sensitivity and specificity, equating to a balanced accuracy of 96.88%. Identified metabolites belonged to biochemical pathways of omega-3 and omega-6 fatty acids, sphingolipids, dipeptides, purines, and tryptophan metabolism. Dipeptides emerged as the most critical molecules for severe disease classification. Additionally, a previously reported trend between serotonin and platelets in DHF patients was expanded upon here, revealing a major depletion of serotonin, but not platelets, in DSS patients. In this study, the perturbed metabolome was used for disease state classification and exploration of the biochemistry of severe dengue disease pathology.IMPORTANCEThe international burden of dengue is intensifying, as the number of reported cases in only the first 5 months of 2025 exceeded that of the previous annual high in 2023. The occurrence of deadly severe manifestations of dengue disease will escalate as the total cases rise, and pediatric patients are at greater risk of developing the rapidly progressing severe dengue diseases than adults. Suboptimal vaccines, lack of clinically approved therapeutics, and no methodologies for prognosis of severe disease exacerbate the difficulty of preventative and supportive care. Because human metabolism is rapidly altered due to infection, perturbations in patients' circulating metabolome can be attributed to dengue disease and correlated to severity. This study contributes metabolic biomarkers of dengue disease in pediatric patients from Nicaragua, indicating that metabolic biomarkers are conserved across patients of different ages and geographic and genetic backgrounds. With validation across many cohorts, there is potential to improve diagnostics.

Indexed as

DengueMetabolomeSevere DengueAdolescentBiomarkersChildChild, PreschoolChromatography, LiquidDengue VirusFemaleHumansInfantMaleMetabolomicsNicaraguaTandem Mass SpectrometryBiomarkersbiomarkerdenguefeverhemorrhagic feverinfectious diseaselipidomicsmetabolomicspediatricserumsevere disease

Identifiers

PMID41159750
PMCPMC12645983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.